Show simple item record

dc.contributor.advisorMichael A. M. Davies, Noubar Afeyan and Todd Thorsen.en_US
dc.contributor.authorYadav, Shailendraen_US
dc.contributor.otherSystem Design and Management Program.en_US
dc.date.accessioned2010-10-12T19:04:27Z
dc.date.available2010-10-12T19:04:27Z
dc.date.copyright2010en_US
dc.date.issued2010en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/59276
dc.descriptionThesis (S.M. in System Design and Management)--Massachusetts Institute of Technology, Engineering Systems Division, 2010.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (p. 63-65).en_US
dc.description.abstractAdvances in microfluidics in the last two decade have created a tremendous technological value which is shaping genomics; drug discovery; proteomics; and point-of-care diagnostics. The positive impact has resulted in faster analysis time, increased throughput and reduced cost amongst other important benefits. Yet, the life sciences end-users and the microfluidics players themselves are far from fully capturing the value. Author's own observation based on the experience at a leading genomics research institute, where multiple efforts to implement microfluidics technologies hardly succeeded, supports this fact. The failure to fully capture value has serious implications for the vendors developing microfluidics and the researchers employing these technologies. What are the reasons for this failure? What could be done to increase the value capture? Using well-established management frameworks, such as, s-curve, adopter's distribution model, the thesis studied the nature of value creation and value capture. Survey was used to quantify the impact and the diffusion and adoption of microfluidics technologies, as the respective indicators of value creation and value capture. The data support the insight obtained from the conceptual frameworks that microfluidics is still an immature technology. It also shows that immature technology is the primary reason for lack of full value capture rather than the lack of killer application or niche market - commonly reported reasons in the literature. As an immature technology, microfluidics is thus far still only in the hands of users who are innovators and early adopters - the academic laboratories and the research institutes. The application segments which have seen the most value capture are Genomics and Point-of-care diagnostics. The application segment which has seen the least value capture is Drug discovery. This thesis concludes with the recommendations for short and long term strategies for increasing value capture and accelerating the adoption of microfluidics.en_US
dc.description.statementofresponsibilityby Shailendra Yadav.en_US
dc.format.extent78 p.en_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectEngineering Systems Division.en_US
dc.subjectSystem Design and Management Program.en_US
dc.titleAnalysis of value creation and value capture in microfluidics marketen_US
dc.typeThesisen_US
dc.description.degreeS.M.in System Design and Managementen_US
dc.contributor.departmentSystem Design and Management Program.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Engineering Systems Division
dc.identifier.oclc668088592en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record